BP000031-GD5: Recombinant Heparinase I from Flavobacterium heparinum
Source: E. coli-derived.
Specific activity >100 IU/mg. One international unit (IU) of recombinant Heparinase I is defined as the amount of enzyme that will liberate 1.0 umole unsaturated oligosaccharides from porcine mucosal heparin per minute at 30°C and pH 7.0.
Purity >95% by SDS-PAGE.C023P: Avelumab Biosimilar, PD-L1 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade avelumab biosimilar specifically binds to the programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and B7-1.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by avelumab.BP4200: Recombinant Dr. Nuclease (Benzonase Nuclease Alternative)
Source: E. coli-derived.
Specific activity: ≥1.1 x 10^6 U/mg. One unit of Dr. Nuclease is defined as the amount of enzyme required to produce a change in absorbance at 260 nm of 1.0 in the time of 30 minutes, under optimum conditions with excess substrate.
Purity: ≥95% by SDS-PAGE and ≥99% by SEC-HPLC. It does not contain any antimicrobial preservatives or protein stabilizers except glycerol (of synthetic origin).BP4200-GMP: Recombinant Dr. Nuclease (Benzonase Nuclease Alternative), GMP Grade
Source: E. coli-derived.
Predicted molecular mass: ~28 kDa.
Specific activity: ≥1.1 x 10^6 U/mg. One unit of Dr. Nuclease is defined as the amount of enzyme required to produce a change in absorbance at 260 nm of 1.0 in the time of 30 minutes, under optimum conditions with excess substrate.
Purity: ≥95% by SDS-PAGE and ≥99% by SEC-HPLC. It does not contain any antimicrobial preservatives or protein stabilizers except glycerol (of synthetic origin).
Formulation: 0.2 μM filtered solution (250 units/ul) of 20 mM Tris-HCl, pH 8.0, 2 mM MgCl2, 2 mM NaCl, 50% Glycerol.
Endotoxin level: ≤0.01 EU/1000 units following 2020 ChP 1143 USP <85>.
Protease activity: No detectable protease activity using casein as substrate.
Residual host cell protein: ≤10.0 ppm by ELISA.
Mycoplasma: negative by qPCR method.
Bioburden: negative following 2020 ChP 1105 USP <61>.
Residual heavy metal: ≤10.0 ppm following 2020 ChP 0821 USP <32>.C026P: Nivolumab Biosimilar, PD-1 Monoclonal Antibody
Recombinant Humanized IgG4 Monoclonal Antibody.
Specificity/Sensitivity: The research grade nivolumab biosimilar specifically binds to PD-1, antagonizing its interaction with its known ligands PD-L1 and PD-L2.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by nivolumab.C024P: Atezolizumab Biosimilar, PD-L1 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade atezolizumab biosimilar specifically binds to the human PDL1 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by atezolizumab.C037P: Tremelimumab Biosimilar, CTLA-4 monoclonal antibody
Recombinant Chimeric IgG2 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade tremelimumab biosimilar specifically binds to the human protein receptor CD152 / CTLA4.
Applications: ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by tremelimumab.BP003083: Recombinant Human Nectin-3 / CD113 Protein
Source: mammalian cells.
Purity: > 95% by Bis-Tris PAGE and HPLC.C050P: Ipilimumab Biosimilar, CTLA-4 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab.BP003057: Recombinant SARS-CoV-2 Spike S-Fc Protein
Source: HEK 293 cells.
Purity: > 95% by PAGE under reduced condition, and SEC-HPLC.BP003050: Recombinant SARS-CoV-2 Spike RBD-Fc-Avi (S Protein)
Source: mammalian cells.
Purity: > 95% by PAGE under reduced condition, and SEC-HPLC.